Drugs and Devices

FDA approves Imbruvica to treat chronic lymphocytic leukemia

On Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients who have received at least one previous therapy.
Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares